Anti-venom Market Report by Growth Enablers, Geography, Restraints and Trends – Global Forecast To 2026 | BTG plc. Laboratorios Silanes, CSL Limited, Pfizer, Inc., Merck & Co., Inc.

Anti-venom is a medication majorly used to treat snake bites and it can also be used to treat bites from scorpions, spiders or other reptiles. It is made by fractionating the blood of the donor (horse or sheep), which is hyper immunized with snake venom. These products are available in either lyophilized or liquid forms. Anti-venom is the only effective therapy against snake bites and they also save patients from cell and tissue necrosis, thus helping save vital organs.

Key players operating in the anti-venom market include BTG plc. Laboratorios Silanes, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., and Rare Disease Therapeutics Inc.

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1249

Market Dynamics

The incidence of animal bite such as snake, and scorpion is high. High incidence of poisonous animal bite is also expected to be a major factor driving demand for anti-venom in the near future.

For instance, according to the data published by World Health Organization (WHO), in 2018, it was estimated that globally, the incidence of snakebite is around 4.5 to 5.4 million bites from venomous and non-venomous snakes, out of which around 1.8 million to 2.7 million cases of snakebite are envenoming.

Increasing initiatives by government and various other organizations to increase awareness about snake bite and its treatment is further expected to support adoption of anti-venoms during forecast period. For instance, World Health Organization (WHO), in June 2017, added snakebite to its priority list of neglected tropical disease, which would result in more focused effort to prevent death from snakebite, thus boosting growth of the anti-venom market.

Robust pipeline and frequent approval of novel anti-venom is expected to drive growth of the global anti-venom market

University of Arizona is developing polyvalent F(ab)2 Equine, an anti-venom indicated for the treatment against the North American coral snake (Micrurus) bite. Currently (2018), the product is under phase 3 clinical trial and is expected to get approval in the near future. Presence of such new products in pipeline is expected to support the global anti-venom market growth over forecast period.

Approvals and launches of novel drugs in key regions are also expected to be a major factor to drive anti-venom market growth during the forecast period. For instance, in October 2018, Silanes Laboratories received the U.S. Food and Drug Administration (FDA) approval for Anavip, an anti-venom against the bite of snakes of the Crotalus family, which includes the rattlesnake. In 2017, Rare Disease Therapeutics, Inc. partner of Silanes Laboratories, launched Anavip in the U.S. market.

Furthermore, key players in the market are focusing on increasing shelf life and extending the expiry date of its products. For instance, in September 2018, BTG plc. announced that the U.S. Food & Drug Administration (FDA) has granted approval for updating the shelf life of CroFab Crotalidae Polyvalent Immune Fab (Ovine) to 60 months.

In 2018, Pfizer, Inc. worked with the U.S. Food and Drug Administration (FDA), to extend the expiration date of Antivenin’s Lot No. L67530 for an additional 12 months.

The global anti-venom market size was valued at US$ 504.9 Mn in 2018, and is expected to witness a CAGR of 4.7% during the forecast period (2018 – 2026).

Detailed Segmentation:

Global Anti-venom Market, By Animal Type :
Snake
Scorpion
Spider
Others

Global Anti-venom Market, By Anti-venom Type:
Monovalent
Polyvalent

Global Anti-venom market, By Distribution Channel:
Hospital
Retail Pharmacies
Others

Global Anti-venom Market, By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1249

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.